Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination.
Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies.
The quality of reports of randomized trials in multiple sclerosis: a review.
Interleukin-1beta promotes repair of the CNS.
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
Teva announces U.S. FDA approval of three-times-a-week COPAXONE® (glatiramer acetate injection) 40mg/mL
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
Assessment and Imaging of the Cerebrovascular Glycocalyx.
Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Yes.
MS clinical trials: what can subgroup analyses teach us?
Management of worsening multiple sclerosis with mitoxantrone: a review.
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis.
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis.
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Biogen Idec to acquire Fumapharm AG; Consolidates ownership of oral compound BG-12 being studied for multiple sclerosis
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kcyB (NF-kcyB) and Extracellular Signal-regulated kinase 1 and 2 (ERK1/2) and Mitogen Stress activated kinase 1 (MSK1) signaling.
Headaches in multiple sclerosis: Cross-sectional study of a multiethnic population.

Pages